Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01189 (
beta-endorphin
)
21,003
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Existence of a reciprocal neuroendocrine-immune relationship led us to study an immunomodulatory role for the
corticotropin-releasing factor
(
CRF
) which is a low molecular weight peptide neurohormone of the neuroendocrine system. In the present study, the
CRF
-induced modulation of natural killer (NK) cell-mediated lysis (CML) was investigated. The pretreatment for 16-18 h of human peripheral blood mononuclear cells (MNC) with
CRF
in nanomolar concentrations caused a statistically significant increase in the CML function of NK cells as measured against K562 target cells in the 4-h 51Cr-release assay. The maximum stimulation occurred at a final concentration of 1 nM
CRF
despite some variability from one blood donor to another. The depletion of monocytes from MNC abolished the stimulatory effect of
CRF
but the effect was reconstituted by the supplementation of monocyte-derived interleukin-1 (IL-1), suggesting the involvement of IL-1 in the stimulation of NK cell-mediated lysis. Additionally, the
CRF
-induced stimulatory effect was inhibited by specific antibodies to IL-1 (anti-IL-1) or
beta-endorphin
(anti-beta E), indirectly suggesting that IL-1 and beta E may act as the mediators of stimulation by
CRF
of NK cell function. Based on these in vitro studies, we hypothesize that the
CRF
modulates NK cell-mediated lysis via initial stimulation of monocytes to produce IL-1 triggering the release by B cells of beta E for the stimulation of NK cell function.
...
PMID:Modulation of natural killer cell-mediated lysis by corticotropin-releasing neurohormone. 187 75
Neuroendocrine responses to psychosocial pressures have been well characterized. The defence reaction is followed by increased activity of the sympathetic nervous system. Essential hypertension might be induced by such mechanisms. The defeat reaction is characterized by increased activity along the
corticotropin releasing factor
-
adrenocorticotropin
hormone-cortisol axis, resulting in the inhibition of gonadotropin secretion. Such endocrine disturbances are followed by metabolic aberrations, and probably also by the accumulation of visceral fat. Subjects with abdominal fat accumulation (high waist/hip circumference ratio, WHR) have recently been found to exhibit a number of psychosocial handicaps, together with endocrine aberrations characteristic of the defence and, in particular, the defeat reaction, as well as the associated circulatory and metabolic aberrations. Such abnormalities, including the WHR itself, are established risk factors for cardiovascular disease and diabetes. It is postulated that increased WHR is a symptom of chronic hypothalamic arousal as a result of a defeat reaction to psychosocial pressures. This might lead to the development of disease via circulatory and metabolic derangements.
...
PMID:Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? 189 41
Neurointermediate lobes (NILS) of the pituitary glands of adult male Sprague-Dawley rats were incubated in media in the presence of
corticotropin-releasing factor
(
CRF
), a stimulator of proopiomelanocortin (POMC) peptide release. Alpha-helical
CRF
, a peptide known to inhibit
CRF
induced POMC peptide release from the anterior pituitary, was incubated with NILS for a period of 90 min, to study its potential ability to modulate peptide release from the intermediate lobe. The alpha-helical peptide reduced
beta-endorphin
release from NILS, as measured by radioimmunoassay (RIA), when added for the entire incubation, or when added 30 min after start of the incubation period, with
CRF
present. Alpha-helical
CRF
alone reduced
beta-endorphin
release, as compared to control or
CRF
-treated lobes. Ultrastructural examination of intermediate lobes fixed at the end of incubations revealed a reduction in the numbers of Golgi-associated dense granules, an indicator of new peptide synthesis, in intermediate lobe tissue treated with alpha-helical
CRF
alone, both peptides together, or with
CRF
followed by alpha-helical peptide. The in vitro studies demonstrate the effectiveness of the antagonist peptide on intermediate lobe peptide secretion, thereby extending its effects to both POMC-secreting areas of the pituitary gland.
...
PMID:Interaction of corticotropin-releasing factor (CRF) and alpha-helical CRF on rat neurointermediate lobes: in vitro studies. 189 31
The effect of inhibiting protein synthesis on concentrations of
corticotropin-releasing factor
(
CRF
) in rat brain and plasma
adrenocorticotropin
(ACTH) was assessed following the administration of the general protein synthesis inhibitor anisomycin. Compared with vehicle-injected controls, protein synthesis inhibition resulted in significantly reduced
CRF
immunoreactivity (CRF-ir) in median eminence within 1 h (p less than 0.01), remained decreased after 4 h (p less than 0.025), and was nonsignificantly decreased after 24 h. Plasma ACTH levels were greatly increased within 1 h posttreatment (p less than 0.0005), continued elevated after 4 h (p less than 0.01), and returned to normal levels after 24 h.
CRF
-ir measured in other brain areas 24 h after anisomycin showed decreased levels in medulla-pons (p less than 0.025) and neurointermediate lobe of pituitary (p less than 0.05), with no change noted in frontal cortex, hippocampus, midbrain-thalamus, or cerebellum. Overall these data show that blockade of normal protein synthesis with anisomycin can elicit changes in
CRF
-ir and ACTH content.
...
PMID:Effect of protein synthesis inhibition on brain corticotropin-releasing factor and plasma adrenocorticotropin. 196 65
Stress, of both physical and emotional origin, has effects on the reproductive system. Although both ACTH and glucocorticoids are elevated in stress, there is little evidence that these hormones directly affect gonadotropin secretion or ovulation.
Corticotropin-releasing factor
(
CRF
) does interact with gonadotropin-releasing hormone (GnRH)-producing neurons, probably through an opioidergic pathway, suppressing gonadotropin secretion. Opioids, primarily
beta-endorphin
, originating through
CRF
-independent mechanisms in the brain or even the pituitary may also inhibit GnRH production. Tonic, pulsatile gonadotropin secretion is inhibited by stress and by administered morphine, but morphine does not block the estrogen-induced preovulatory surge in primates. Accordingly, impaired follicular development appears to be the most common cause of reproductive dysfunction attributable to stress in the human female. New developments in the understanding of the role of stress in reproduction must take into consideration the many differences between the hormonal responses to stress in the human and laboratory animals.
...
PMID:The role of stress in female reproduction: animal and human considerations. 196 47
Bilateral simultaneous blood samples were taken from the inferior petrosal sinuses of nine patients with Cushing's disease for measurement of
adrenocorticotropin
(ACTH), vasopressin (AVP), prolactin, growth hormone, luteinising hormone (LH), and follicle stimulating hormone (FSH). Inter-sinus gradients for ACTH (range 3.3-18.2) and AVP (2.0-375) correctly lateralised the microadenoma in seven of these patients. One additional patient showed an increased gradient for AVP but not ACTH on the side of the tumour. The correlation between the AVP and ACTH concentrations in the petrosal sinus draining the microadenoma was significant. Petrosal sinus plasma concentrations of prolactin and growth hormone were also significantly higher on the side of the tumour than on the non-tumour side. Evidence against a non-specific tumour effect on the secretion of all pituitary hormones was the fact that in most cases the gradients for LH and FSH were not significant. It is proposed that increased delivery of AVP to part of the pituitary may result from an aberrant blood supply, and that AVP may interact with
corticotropin releasing factor
to promote tumour growth and ACTH release.
...
PMID:Arginine vasopressin in Cushing's disease. 197 Jan 7
The hypothalamus is a major source of afferents to the parabrachial nucleus (PB), but the neurotransmitters in this pathway are largely unknown. In this study, we examine the neuropeptide immunoreactivities of neurons in the hypothalamus that project to the PB by using the combined retrograde fluorescence-immunofluorescence method. After injections of the fluorescent tracer fast blue into the PB, retrogradely labeled neurons were observed in the paraventricular, dorsomedial, ventromedial, median preoptic, and anteroventral periventricular hypothalamic nuclei; in the dorsal, retrochiasmatic, and lateral hypothalamic areas; and in the medial and lateral preoptic areas. Our results show that at least five distinct neuropeptide-immunoreactive cell populations in the hypothalamus project to the PB. In the perifornical lateral hypothalamus, many neurotensin (NT)-,
corticotropin-releasing factor
-, dynorphin (DYN)-, angiotensin II (AII)-, and galanin-like immunoreactive (-ir) neurons were retrogradely labeled. A cluster of retrogradely labeled neurons in the juxtacapsular lateral hypothalamus stained with an antiserum against alpha-melanocyte stimulating hormone (alpha MSH). Over 50% of the retrogradely labeled cells in the arcuate nucleus were
adrenocorticotropin
(ACTH)-or alpha MSH-ir. Many alpha MSH- and ACTH-ir, and a few DYN-, NT- and AII-ir neurons in the retrochiasmatic area were retrogradely labeled. Only small numbers of double-labeled neurons were found in the paraventricular nucleus, and, of these, enkephalin-ir and dynorphin-ir neurons were the most common. Somatostatin-ir cells in the hypothalamus were rarely double-labeled. The chemical coding of these hypothalamic projections to the PB may provide important clues to the functional organization of these descending pathways.
...
PMID:Neuropeptide organization of the hypothalamic projection to the parabrachial nucleus in the rat. 197 10
There is presently no consensus as to the nature of the catecholaminergic influence on the regulation of
corticotropin-releasing factor
. The potential role that the alpha-adrenergic system plays was investigated by measuring hypothalamic
corticotropin-releasing factor
-like immunoreactivity and plasma
adrenocorticotropin
, following manipulation of alpha-1 and alpha-2 adrenergic receptor activation. Administration of the alpha-1 agonist methoxamine did not significantly alter either plasma
adrenocorticotropin
or hypothalamic
corticotropin-releasing factor
. Administration of the alpha-2 agonist clonidine resulted in a 24-fold increase in plasma
adrenocorticotropin
and a significant decrease in median eminence
corticotropin-releasing factor
, consistent with its release.
Corticotropin-releasing factor
in the remainder of the hypothalamus was not altered. Concurrent administration of clonidine with the selective alpha-2 antagonist yohimbine prevented the clonidine-induced changes in plasma
adrenocorticotropin
and hypothalamic
corticotropin-releasing factor
, consistent with the clonidine effect being mediated through alpha-2 receptors. Concurrent administration of clonidine with methoxamine did not prevent these effects, suggesting that the effect of clonidine was not mediated through presynaptic inhibition of noradrenergic adrenergic neurotransmission. Inhibition of protein synthesis by anisomycin induced changes in
corticotropin-releasing factor
and
adrenocorticotropin
which were not altered by combined treatment with methoxamine or clonidine. These data suggest differential roles for alpha-1 and alpha-2 systems in the regulation of
corticotropin-releasing factor
. Results from alpha-2 adrenergic activation were consistent with stimulation of
corticotropin-releasing factor
release, an effect mediated by a postsynaptic alpha-2 mechanism.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Differential alpha-1 and alpha-2 adrenergic effects on hypothalamic corticotropin-releasing factor and plasma adrenocorticotropin. 198 Jan 44
Central neurotransmitter and/or neuromodulator candidates reported to affect gastric acid secretion are: (excitatory) acetylcholine, thyrotropin releasing hormone, GABA, oxytocin; (inhibitory) noradrenaline, adenosine, bombesin, calcitonin-gene related peptide,
corticotropin releasing factor
,
beta-endorphin
, neurotensin, neuropeptide Y, insulin-like growth factor II and prostaglandins. Regulation of gastric acid secretion by central administration of these substances in experimental animals such as rats and dogs are briefly reviewed, and central inhibitory mechanisms of this function are discussed based on our studies with noradrenaline and bombesin. Roles of hypothalamic nuclei such as the ventromedial nucleus and the lateral hypothalamus in regulation of autonomic nerve activities are also described as an introductory note.
...
PMID:[Central neurotransmitters and regulation of gastric acid secretion]. 198 Jun 59
Corticotropin
releasing factor, a 41 amino acid peptide, has been localized in climbing fibers and mossy fibers in the cat's cerebellar cortex. In the present study,
corticotropin releasing factor
was iontophoretically applied to Purkinje cells, isolated extracellularly, to assess the effect of this peptide on the firing rate of the neuron. By itself
corticotropin releasing factor
had little or no effect on cellular activity. However, this peptide potentiated the excitatory effects of aspartate and glutamate, the putative neurotransmitters of the climbing fiber and mossy fiber-parallel fiber systems, respectively. In addition,
corticotropin releasing factor
blocked the suppressive effects induced by the iontophoretic application of GABA. Finally, it shortened or eliminated the period of suppression produced by activation of climbing fibers in the cerebellar cortex. These data suggest that
corticotropin releasing factor
functions as a neuromodulator rather than as a neurotransmitter in cerebellar circuitry.
...
PMID:Neuromodulatory effects of corticotropin releasing factor on cerebellar Purkinje cells: an in vivo study in the cat. 198 66
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>